Disc Medicine (IRON) outlined its recent pipeline progress and strategic priorities for 2026. Key Business Objectives and Milestones for 2026: Bitopertin: GlyT1 Inhibitor – Anticipate FDA approval decision regarding NDA for bitopertin for the treatment of EPP under the CNPV program; Successful launch and initial commercialization of bitopertin in the US, if approved; Continue enrollment of the global, confirmatory APOLLO study with topline data expected by early 2027. DISC-0974: Anti-hemojuvelin Antibody – Progress ongoing Phase 2 MF anemia trial with updated data expected H2 2026; Conduct End of Phase 2 meeting with the FDA about DISC-0974 in MF anemia in H2 2026; Initiate a Phase 2 study of DISC-0974 in patients with anemia and inflammatory bowel disease. DISC-3405: Anti-TMPRSS6 Antibody – Progress ongoing Phase 2 PV trial with updated data expected H2 2026; Progress ongoing Phase 1b SCD trial with updated data expected H2 2026
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IRON:
- Disc Medicine price target raised to $120 from $115 at Morgan Stanley
- Jefferies sees ‘overreaction’ to article on Disc Medicine’s EPP approvability
- Disc Medicine (IRON): Constructive FDA Dialogue and APOLLO Progress Support Buy Rating Despite Volatility
- BMO Capital says call with Disc management clarifies active FDA dialogue
- TD Cowen says Disc Medicine remains confident, bito timeline under CNPV intact